Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), ("Akers Bio" or
the "Company"), a medical device company focused on reducing the
cost of healthcare through faster, easier diagnostics, introduced
two new breath tests to the U.S. market from the Company's Akers
Wellness division at the World Congress on Anti-Aging Medicine in
Hollywood, Florida, USA last week.
BreathScan® OxiChekTM ("OxiChek™") and BreathScan® KetoChekTM
("KetoChek™"), together with the Bluetooth®-enabled reading device,
BreathScan LyncTM - which synchs via an app on any mobile device -
will enable users to monitor trends in critical metabolic
processes. The products will provide healthcare professionals,
suppliers of nutritional supplements and weight loss plans, as well
as health coaches, the ability to more effectively demonstrate,
monitor and adjust the efficacy of their products and the progress
of their clients. These products may also provide such customers
with an opportunity for significant revenue enhancement through
distribution for in-office and at-home use of the devices.
OxiChek™ is the first disposable breath test to rapidly
determine levels of oxidative stress (free radicals) in the body.
OxiChek™ measures the most abundant free radicals, including
superoxides, hydrogen peroxide and aldehydes – unlike some
pre-existing devices which measure only one. Frequent use of
OxiChek™ may help users comply with and adhere to their regimen of
nutritional supplementation for management of oxidative stress,
which is implicated in many diseases including cardiac, cancer and
arthritic diseases.
KetoChek™ is a second generation enhancement of the Company's
METRON® breath ketone test. KetoChek™, to our knowledge, is the
only disposable breath-based diagnostic device that provides rapid,
quantitative assessment of the presence of ketones, to determine if
the subject is in the optimal fat-burning state for weight loss,
known as ketosis. Achieving a state of ketosis is a goal of many
individuals following low carbohydrate, ketogenic diets. KetoChek™
is a simple, non-invasive test to track and monitor for ketosis in
individuals interested in maximizing weight loss, as well as
endurance athletes wanting to activate fat-burning metabolism.
The innovative BreathScan LyncTM device works with both OxiChek™
and KetoChek™, to display and track results over time via
Bluetooth®, to any iOS (Apple) or Android mobile device.
"We believe that personalized health information is the wave of
the future and that this suite of BreathScan products, including
OxiChek™, KetoChek™ and the BreathScan Lync™, will provide
tremendous value to healthcare professionals, consumers, and diet
and supplement manufacturers within the health and wellness
industry," said Raymond F. Akers, Jr. PhD, Co-founder and Executive
Chairman.
"Our KetoChek™ test can help individuals achieve ketosis, which
is a state of optimal fat burning, while OxiChek™ can help them
better optimize lifestyle and supplement utilization to control
free radical levels. Since higher free radical levels have
been shown to correlate with age, OxiChek™ is providing important
information that can greatly enhance an individual's ability to
take control of their aging process," continued Dr. Akers.
"Health and wellness is a trillion dollar business globally and
our proprietary technology for testing breath condensate is a
highly effective diagnostic tool for professionals and consumers in
this industry. Whether in health and wellness or medical
diagnostics, our faster, easier diagnostic tests provide
information that make lives better," added Dr. Akers.
The Company is in discussions with a number of strategic
partners specializing in the health and wellness industry with
regards to the commercialization of OxiChek™, KetoChek™, and
BreathScan Lync™.
ABOUT AKERS BIOSCIENCES, INC.
Akers Biosciences develops, manufactures, and supplies rapid
screening and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbiosciences.com. Follow us on Twitter
@AkersBio.
Cautionary Statement Regarding Forward Looking
Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
CONTACT: For more information:
Akers Biosciences, Inc.
Raymond F. Akers, Jr. PhD
Executive Chairman of the Board
Tel. +1 856 848 8698
finnCap (UK Nominated Adviser and Broker)
Geoff Nash / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500
Taglich Brothers, Inc. (US Investor Relations)
Chris Schreiber
Tel. +1 917 445 6207
Vigo Communications (UK Investor Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7016 9570
akers@vigocomms.com
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Apr 2023 to Apr 2024